Ph.D. Jay R. Luly - 19 Dec 2022 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
President and CEO, Director
Signature
/s/ Nathaniel S. Gardiner as attorney-in-fact
Issuer symbol
ENTA
Transactions as of
19 Dec 2022
Net transactions value
+$399,910
Form type
4
Filing time
19 Dec 2022, 18:50:58 UTC
Previous filing
16 Dec 2022
Next filing
15 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTA Common Stock Options Exercise $399,910 +14,500 +1.9% $27.58 788,305 19 Dec 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTA Stock Option (Right to Buy) Options Exercise $0 -14,500 -21% $0.000000 55,500 19 Dec 2022 Common Stock 14,500 $27.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 100% of the shares subject to the option are fully vested and exercisable.